Key result
Adriamycin (5 or 10 mg/kg) administered immediately after abdominal irradiation reduced the LD50/7 days by 300-400 R and reduced post-irradiation compensatory hyperplasia without reducing surviving crypts.
Why the study?
Does adriamycin alter the post-irradiation proliferative response and survival in the mouse jejunum?
Does adriamycin alter the post-irradiation proliferative response and survival in the mouse jejunum?
Adriamycin reduces post-irradiation compensatory hyperplasia and lowers the LD50/7 days in mice without reducing the number of surviving crypts.
The influence of adriamycin on the post-irradiation proliferative response of the mouse jejunum was examined. Doses of either 5 or 10 mg/kg of adriamycin administered immediately after abdominal irradiation reduced the LD50/7 days by 300-400 R. Neither dosage of the drug reduced the number of surviving crypts, as measured by the crypt isolation and microcolony techniques, for a given radiation exposure. However, both drug dosages reduced the amount of post-irradiation compensatory hyperplasia, as measured by 3H-thymidine incorporation.
No takes yet. Share an insight, caveat, or question.
Burholt et al. (1975) studied Post-irradiation proliferative response. Adriamycin vs. Radiation alone was evaluated on LD50/7 days, surviving crypts, and post-irradiation compensatory hyperplasia. Adriamycin (5 or 10 mg/kg) administered immediately after abdominal irradiation reduced the LD50/7 days by 300-400 R and reduced post-irradiation compensatory hyperplasia without reducing surviving crypts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: